TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05042167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 4 total resistance exercises that target all major muscle groups.
Study: NCT04100720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve Transfemoral Tricuspid Valve
Description: The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
Study: NCT05820841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-miniCHOP + Acalabrutinib
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-miniCHOP
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks
Study: NCT04967287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyopiaX
Description: MyopiaX treatment twice a day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia control spectacles
Description: To be used all as prescribed
Study: NCT05999578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis support before, during and at the end of cardiac MRI exam
Study: NCT04549571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid iCanDecide - ESE website
Description: Utilize the iCanDecide - ESE website

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid iCanDecide - S website
Description: Utilize the iCanDecide - S website
Study: NCT05229588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 4 MG Injection [Zepzelca]
Description: Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate.
Study: NCT05254925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen oil with 6% Bemotrizinol
Description: Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen oil vehicle
Description: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dispersion of 6% BEMT in petrolatum
Description: Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum

Intervention type: OTHER
Group type: OTHER
Intervention: Petrolatum vehicle
Description: Petrolatum vehicle
Study: NCT05316766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical rehabilitation
Description: Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
Study: NCT04718402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study: NCT04872504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acumen HPI-enabled EV1000 screen
Description: Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
Study: NCT06259604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI
Description: Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI+kangaroo care
Description: Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
Study: NCT05316766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation interactive table
Description: Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
Study: NCT04840394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB018
Description: BDB018 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB018
Description: BDB018 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study: NCT04514406

Intervention type: DEVICE
Intervention: APERTO OTW DCB
Description: Drug Coated Balloon Angioplasty
Study: NCT05489718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 2 IBI324 of multiple IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 2 IBI324 of single IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 1 IBI324 of single IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 3 IBI324 of single IVT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI324
Description: Dose 3 IBI324 of multiple IVT injection
Study: NCT05957328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Pyrophosphate Liposomal
Description: Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous ascorbate
Description: one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
Study: NCT04549571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview
Study: NCT04949633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandins
Description: Second cervical ripening lasting a maximum of 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Induction of labor with oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Induction of labor with oxytocin.
Study: NCT06435494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic use of patient reported outcome measures in clinical work with the patients
Description: Se description of the arms
Study: NCT04549571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training
Study: NCT05844254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: novel overlapping rotated double (NORD) flap
Description: After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: novel overlapping rotated double (NORD) flap
Description: After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
Study: NCT04116619

Intervention type: OTHER
Intervention: Guided Imagery Laboratory Session
Description: On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol.

Intervention type: OTHER
Intervention: Guided Imagery Laboratory Session
Description: On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol.
Study: NCT05743413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Armeo Spring physiotherapy
Description: Study subjects will undergo physiotherapy sessions using the Armeo Spring device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Study subjects will undergo standard physiotherapy sessions.
Study: NCT05454241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD7 CAR-T
Description: Universal CAR-T cells targeting CD7
Study: NCT05538585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral
Study: NCT05295836

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLYCEROL
Description: Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
Study: NCT04825704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
Study: NCT06425406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal cannula
Description: In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
Study: NCT06115512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA111
Description: AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study: NCT04576416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI augmented training and clinical feedback
Description: The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group.
Study: NCT05834179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold endotracheal tube
Description: patients who were intubated with an ETT which kept in the fridge.
Study: NCT05693649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Direct Patient Outreach
Description: Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Colonoscopy Only
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Colonoscopy Only
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Sequential Choice
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Patient Outreach: Sequential Choice
Description: Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit-Based Nudge/Text
Description: Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit-Based Nudge/Text
Description: Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nudge/Text
Description: Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nudge/Text
Description: Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Nudge/Text
Description: Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
Study: NCT05976906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
Description: 1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results.
Study: NCT06249880

Intervention type: OTHER
Intervention: Observation
Description: This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
Study: NCT04856215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90-Yttrium-labelled anti-CD66 monoclonal antibody
Description: The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient.
Study: NCT04211649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 days of antibiotherapy
Description: Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
Study: NCT04549571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Receive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Utilize the CDB
Study: NCT05124600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SavvyHealth
Description: Participants will use the new app, SavvyHealth, for 21 days.
Study: NCT04549571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Utilize the CDB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Utilize the CDB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Utilize the CDB